Home › Compare › NBSE vs SBUX

NBSE vs SBUX: Dividend Comparison 2026

NBSE yields 529.10% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NBSE wins by $95355.80M in total portfolio value
10 years
NBSE
NBSE
● Live price
529.10%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95355.96M
Annual income
$69,511,989,565.27
Full NBSE calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — NBSE vs SBUX

📍 NBSE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNBSESBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NBSE + SBUX cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NBSE pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBSE
Annual income on $10K today (after 15% tax)
$44,973.54/yr
After 10yr DRIP, annual income (after tax)
$59,085,191,130.48/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, NBSE beats the other by $59,085,130,664.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBSE + SBUX for your $10,000?

NBSE: 50%SBUX: 50%
100% SBUX50/50100% NBSE
Portfolio after 10yr
$47678.07M
Annual income
$34,756,030,350.86/yr
Blended yield
72.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

NBSE
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Altman Z
-10.6
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBSE buys
0
SBUX buys
0
No recent congressional trades found for NBSE or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNBSESBUX
Forward yield529.10% ✓2.84%
Annual dividend / share$2.00$2.46 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3% ✓
Portfolio after 10y$95355.96M ✓$167.0K
Annual income after 10y$69,511,989,565.27 ✓$71,136.45
Total dividends collected$93138.90M ✓$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: NBSE vs SBUX ($10,000, DRIP)

YearNBSE PortfolioNBSE Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$63,610$52,910.05$11,121$420.68+$52.5K → NBSE
2$382,606$314,543.11$12,548$648.40+$370.1K → NBSE
3$2,177,551$1,768,162.86$14,440$1,013.98+$2.16M → NBSE
4$11,734,902$9,404,922.59$17,068$1,617.30+$11.72M → NBSE
5$59,924,074$47,367,729.01$20,912$2,649.52+$59.90M → NBSE
6$290,177,156$226,058,396.40$26,875$4,499.29+$290.15M → NBSE
7$1,333,544,009$1,023,054,452.33$36,771$8,014.12+$1333.51M → NBSE
8$5,820,882,501$4,393,990,410.63$54,542$15,197.11+$5820.83M → NBSE
9$24,153,246,984$17,924,902,708.82$89,602$31,242.49+$24153.16M → NBSE
10$95,355,963,839$69,511,989,565.27$167,011$71,136.45+$95355.80M → NBSE

NBSE vs SBUX: Complete Analysis 2026

NBSE — Stock

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Full NBSE Calculator →

SBUX — Consumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this NBSE vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBSE vs SCHDNBSE vs JEPINBSE vs ONBSE vs KONBSE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.